{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:13:36Z","timestamp":1787973216504,"version":"build-2784847793"},"reference-count":68,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Chronic and inappropriate benzodiazepine intake represents an important health and social concern worldwide. The aim of our study was to investigate the effectiveness of P. incarnata L., herba, in reducing benzodiazepine misuse in a real-world population of depressed and anxious patients in a long-term treatment with benzodiazepines. We conducted a retrospective naturalistic study on 186 patients undergoing benzodiazepine downtitration, 93 with the addition of a dry extract of P. incarnata L., herba (Group A), and 93 without any add-on treatment (Group B). Regarding the benzodiazepine dosage variation in the two groups, a repeated measure ANOVA showed a significant effect of time (p &lt; 0.001), group (p = 0.018), and time x group interaction (p = 0.011). We found a significantly higher rate, i.e., of 50%, reduction in Group A vs. Group B at 1 month (p &lt; 0.001) and at 3 months (p &lt; 0.001) and complete benzodiazepine discontinuation at 1 month (p = 0.002) and at 3 months (p = 0.016). Our findings suggest the role of P. incarnata as an effective add-on treatment during benzodiazepine tapering. These findings highlight the need for further studies to better investigate the promising properties of P. incarnata in the management of such a relevant clinical and social issue.<\/jats:p>","DOI":"10.3390\/ph16030426","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T04:04:00Z","timestamp":1678680240000},"page":"426","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Add-On Treatment with Passiflora incarnata L., herba, during Benzodiazepine Tapering in Patients with Depression and Anxiety: A Real-World Study"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5941-5663","authenticated-orcid":false,"given":"Raffaella","family":"Zanardi","sequence":"first","affiliation":[{"name":"Department of Clinical Neurosciences, Vita-Salute San Raffaele University, 20132 Milan, Italy"},{"name":"Department of Clinical Neurosciences, Mood Disorder Unit, IRCCS San Raffaele Institute, 20127 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Carminati","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, Vita-Salute San Raffaele University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9445-2873","authenticated-orcid":false,"given":"Valentina","family":"Fazio","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, Vita-Salute San Raffaele University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania","family":"Maccario","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, Vita-Salute San Raffaele University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Verri","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, Vita-Salute San Raffaele University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Colombo","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, Vita-Salute San Raffaele University, 20132 Milan, Italy"},{"name":"Department of Clinical Neurosciences, Mood Disorder Unit, IRCCS San Raffaele Institute, 20127 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"ref_1","unstructured":"FDA Drug Safety Communication (2023, February 09). FDA Drug Safety Communication on Benzodiazepine, 9\/23\/2020, Available online: https:\/\/www.fda.gov\/media\/142368\/download."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/mp.2010.120","article-title":"The GABAergic deficit hypothesis of major depressive disorder","volume":"16","author":"Luscher","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Zaric Kontic, M., Dragic, M., Martinovic, J., Mihajlovic, K., Brkic, Z., Mitrovic, N., and Grkovic, I. (2023). Prolonged Alprazolam Treatment Alters Components of Glutamatergic Neurotransmission in the Hippocampus of Male Wistar Rats\u2014The Neuroadaptive Changes following Long-Term Benzodiazepine (Mis) Use. Pharmaceuticals, 16.","DOI":"10.3390\/ph16030331"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Tanaka, M., and V\u00e9csei, L. (2022). Editorial of Special Issue \u2018Dissecting Neurological and Neuropsychiatric Diseases: Neurodegeneration and Neuroprotection\u2019. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23136991"},{"key":"ref_5","unstructured":"Institute of Health Metrics and Evaluation (2022, May 14). Global Health Data Exchange (GHDx). Available online: https:\/\/vizhub.healthdata.org\/gbd-results\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1192\/bjp.173.5.433","article-title":"Extent and appropriateness of benzodiazepine use. Results from an elderly urban community","volume":"173","author":"Taylor","year":"1998","journal-title":"Br. J. Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1176\/appi.ps.201800321","article-title":"Benzodiazepine Use and Misuse Among Adults in the United States","volume":"70","author":"Maust","year":"2019","journal-title":"Psychiatr. Serv."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3390\/neurolint14030053","article-title":"Novel Designer Benzodiazepines: Comprehensive Review of Evolving Clinical and Adverse Effects","volume":"14","author":"Edinoff","year":"2022","journal-title":"Neurol. Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/bcp.14165","article-title":"Misuse of benzodiazepines: Prevalence and impact in an inpatient population with psychiatric disorders","volume":"86","author":"Panes","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3390\/neurolint13040059","article-title":"Benzodiazepines: Uses, Dangers, and Clinical Considerations","volume":"13","author":"Edinoff","year":"2021","journal-title":"Neurol. Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"20451253221082386","DOI":"10.1177\/20451253221082386","article-title":"Experiences with benzodiazepine use, tapering, and discontinuation: An Internet survey","volume":"12","author":"Macoubrie","year":"2022","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2125.2012.04418.x","article-title":"Benzodiazepine harm: How can it be reduced?","volume":"77","author":"Lader","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_13","first-page":"28","article-title":"Benzodiazepine use, abuse, and dependence","volume":"66","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/fampra\/cmab143","article-title":"Discontinuation of chronic benzodiazepine use in primary care: A nonrandomized intervention","volume":"39","author":"Fernandes","year":"2022","journal-title":"Fam. Pract."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/978-981-32-9705-0_19","article-title":"Current and Novel Psychopharmacological Drugs for Anxiety Disorders","volume":"1191","author":"Bandelow","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_16","first-page":"CD010677","article-title":"Benzodiazepines versus placebo for panic disorder in adults","volume":"3","author":"Breilmann","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14740338.2018.1429403","article-title":"Risks and benefits of medications for panic disorder: A comparison of SSRIs and benzodiazepines","volume":"17","author":"Quagliato","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/978-981-32-9705-0_20","article-title":"Role of Benzodiazepines in Anxiety Disorders","volume":"1191","author":"Balon","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/fampra\/cmh309","article-title":"Long-term benzodiazepine users in family practice: Differences from short-term users in mental health, coping behaviour and psychological characteristics","volume":"21","author":"Zandstra","year":"2004","journal-title":"Fam. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"595584","DOI":"10.3389\/fpsyt.2020.595584","article-title":"Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options","volume":"11","author":"Garakani","year":"2020","journal-title":"Front. Psychiatry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14656566.2018.1472767","article-title":"Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: A meta-analytic review","volume":"19","author":"Gomez","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3109\/08039481003624173","article-title":"Benzodiazepine tapering: A prospective study","volume":"64","author":"Vikander","year":"2010","journal-title":"Nord. J. Psychiatry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00228-017-2257-8","article-title":"A systematic review of interventions to deprescribe benzodiazepines and other hypnotics among older people","volume":"73","author":"Reeve","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.drugalcdep.2019.02.033","article-title":"The epidemiology of benzodiazepine misuse: A systematic review","volume":"200","author":"Votaw","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"18m12174","DOI":"10.4088\/JCP.18m12174","article-title":"Prevalence and Correlates of Benzodiazepine Use, Misuse, and Use Disorders Among Adults in the United States","volume":"79","author":"Blanco","year":"2018","journal-title":"J. Clin. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jpsychires.2020.05.020","article-title":"Benzodiazepine misuse among adults receiving psychiatric treatment","volume":"128","author":"McHugh","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/YIC.0000000000000316","article-title":"Understanding the effects of chronic benzodiazepine use in depression: A focus on neuropharmacology","volume":"35","author":"Lim","year":"2020","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_28","first-page":"230","article-title":"Stahl\u2019s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, Third Edition","volume":"19","author":"Elbe","year":"2010","journal-title":"J. Can. Acad. Child Adolesc. Psychiatry"},{"key":"ref_29","first-page":"e15816","article-title":"Benzodiazepine Misuse: An Epidemic Within a Pandemic","volume":"13","author":"Sarangi","year":"2021","journal-title":"Cureus"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jamapsychiatry.2022.1150","article-title":"Complex Persistent Benzodiazepine Dependence-When Benzodiazepine Deprescribing Goes Awry","volume":"79","author":"Peng","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/jcpt.13333","article-title":"Benzodiazepines: Thinking outside the black box","volume":"46","author":"Pergolizzi","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Takeshima, M., Aoki, Y., Ie, K., Katsumoto, E., Tsuru, E., Tsuboi, T., Inada, K., Kise, M., Watanabe, K., and Mishima, K. (2022). Attitudes and Difficulties Associated with Benzodiazepine Discontinuation. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph192315990"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"327","DOI":"10.7556\/jaoa.2019.055","article-title":"Complicated Withdrawal Phenomena During Benzodiazepine Cessation in Older Adults","volume":"119","author":"Reeves","year":"2019","journal-title":"J. Osteopath. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/7854_2020_171","article-title":"GABAB Receptors: Anxiety and Mood Disorders","volume":"52","author":"Felice","year":"2022","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2146\/ajhp160712","article-title":"Pregabalin as adjunctive therapy in benzodiazepine discontinuation","volume":"75","author":"Caniff","year":"2018","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.eurpsy.2010.12.004","article-title":"Pregabalin for the discontinuation of long-term benzodiazepines use: An assessment of its effectiveness in daily clinical practice","volume":"27","author":"Bobes","year":"2012","journal-title":"Eur. Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3109\/00952990.2015.1125493","article-title":"Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients","volume":"42","author":"Mariani","year":"2016","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"ref_38","first-page":"CD011481","article-title":"Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users","volume":"3","author":"Baandrup","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"12S","DOI":"10.1097\/00004714-199912002-00003","article-title":"Pharmacologic strategies for discontinuing benzodiazepine treatment","volume":"19","author":"Rickels","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0140-6736(81)92861-0","article-title":"Benzodiazepine withdrawal symptoms and propranolol","volume":"1","author":"Tyrer","year":"1981","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/BF02246214","article-title":"Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: Effects on withdrawal severity and taper outcome","volume":"117","author":"Schweizer","year":"1995","journal-title":"Psychopharmacology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00004714-199804000-00004","article-title":"A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation","volume":"18","author":"Romach","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1192\/bjp.168.4.457","article-title":"A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms","volume":"168","author":"Tyrer","year":"1996","journal-title":"Br. J. Psychiatry"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004714-198702000-00003","article-title":"A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms","volume":"7","author":"Lader","year":"1987","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1176\/ajp.143.12.1590","article-title":"Failure of buspirone to manage benzodiazepine withdrawal","volume":"143","author":"Schweizer","year":"1986","journal-title":"Am. J. Psychiatry"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1176\/appi.ajp.157.12.1973","article-title":"Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy","volume":"157","author":"Rickels","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.drugalcdep.2018.04.028","article-title":"Review: Adjunctive pharmacologic approaches for benzodiazepine tapers","volume":"189","author":"Welsh","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002130050798","article-title":"Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: Effects on withdrawal symptoms and taper outcome","volume":"141","author":"Rickels","year":"1999","journal-title":"Psychopharmacology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2515690X20967323","DOI":"10.1177\/2515690X20967323","article-title":"Valerian Root in Treating Sleep Problems and Associated Disorders\u2014A Systematic Review and Meta-Analysis","volume":"25","author":"Shinjyo","year":"2020","journal-title":"J. Evid.-Based Integr. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Janda, K., Wojtkowska, K., Jakubczyk, K., Antoniewicz, J., and Skonieczna-\u017bydecka, K. (2020). Passiflora incarnata in Neuropsychiatric Disorders\u2014A Systematic Review. Nutrients, 12.","DOI":"10.3390\/nu12123894"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.tips.2018.03.006","article-title":"The Benzodiazepine Binding Sites of GABAA Receptors","volume":"39","author":"Sigel","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ptr.3352","article-title":"Modulation of the \u03b3-aminobutyric acid (GABA) system by Passiflora incarnata L","volume":"25","author":"Appel","year":"2011","journal-title":"Phytother. Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Bruni, O., Ferini-Strambi, L., Giacomoni, E., and Pellegrino, P. (2021). Herbal Remedies and Their Possible Effect on the GABAergic System and Sleep. Nutrients, 13.","DOI":"10.3390\/nu13020530"},{"key":"ref_54","unstructured":"HMPC (2023, March 02). \u201cAssessment Report on Passiflora incarnata L., herba,\u201d Ema\/Hmpc\/669738\/2013, No. November. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/herbal-report\/final-assessment-report-passiflora-incarnata-l-herba_en.pdf."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Publishing, Inc.. [5th ed.].","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jad.2013.04.028","article-title":"Severity classification on the Hamilton Depression Rating Scale","volume":"150","author":"Zimmerman","year":"2013","journal-title":"J. Affect. Disord."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/occmed\/kqv054","article-title":"Hamilton Rating Scale for Anxiety (HAM-A)","volume":"65","author":"Thompson","year":"2015","journal-title":"Occup. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"S467","DOI":"10.1002\/acr.20561","article-title":"Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A)","volume":"63","author":"Julian","year":"2011","journal-title":"Arthritis Care Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000066239","article-title":"On the validity of the Beck Depression Inventory: A review","volume":"31","author":"Richter","year":"1998","journal-title":"Psychopathology"},{"key":"ref_60","unstructured":"JASP Team (2023). JASP (Version 0.17.1) [Computer Software], Free Software Foundation, Inc."},{"key":"ref_61","unstructured":"Microsoft Corporation (2023, February 09). Microsoft Excel. Available online: https:\/\/office.microsoft.com\/excel."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.sapharm.2021.06.001","article-title":"Hospital initiation of benzodiazepines and Z-drugs in older adults and discontinuation in primary care","volume":"18","author":"Coll","year":"2022","journal-title":"Res. Soc. Adm. Pharm."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/JCP.0b013e3181dcb2f3","article-title":"Tapering clonazepam in patients with panic disorder after at least 3 years of treatment","volume":"30","author":"Nardi","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jep.2006.11.021","article-title":"Possible involvement of GABA A-benzodiazepine receptor in the anxiolytic-like effect induced by Passiflora actinia extracts in mice","volume":"111","author":"Lolli","year":"2007","journal-title":"J. Ethnopharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.pbb.2013.07.003","article-title":"Therapeutic potential of GABA (B) receptor ligands in drug addiction, anxiety, depression and other CNS disorders","volume":"110","author":"Kumar","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_66","first-page":"215","article-title":"Attenuation of benzodiazepine dependence in mice by a tri-substituted benzoflavone moiety of Passiflora incarnata Linneaus: A non-habit forming anxiolytic","volume":"6","author":"Dhawan","year":"2003","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/ptr.3400","article-title":"A double-blind, placebo-controlled investigation of the effects of Passiflora incarnata (passionflower) herbal tea on subjective sleep quality","volume":"25","author":"Ngan","year":"2011","journal-title":"Phytother. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1046\/j.1365-2710.2001.00366.x","article-title":"Passionflower in the treatment of opiates withdrawal: A double-blind randomized controlled trial","volume":"26","author":"Akhondzadeh","year":"2001","journal-title":"J. Clin. Pharm. Ther."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/3\/426\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:52:23Z","timestamp":1760122343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/3\/426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":68,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ph16030426"],"URL":"https:\/\/doi.org\/10.3390\/ph16030426","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,10]]}}}